Bhutan vs Malta: HIV/AIDS deaths averted by antiretroviral therapy
Bhutan
39.56 deaths
in 2024
Malta
37.73 deaths
in 2024
Bhutan rank
138th
Malta rank
140th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Bhutan
- Malta
How they compare
Bhutan currently reports 39.56 deaths against 37.73 deaths in Malta, a difference of 1.83 deaths.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Malta ahead.
Bhutan ranks 138th and Malta ranks 140th of 157 countries.
Across the 4 decades both report, Bhutan averaged higher in 1 and Malta in 2.
Head to head by decade
| Decade | Bhutan | Malta | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 2.06 deaths | 7.82 deaths | 5.77 deaths | Malta |
| 2010s | 18.6 deaths | 21.94 deaths | 3.34 deaths | Malta |
| 2020s | 35.68 deaths | 34.89 deaths | 0.7969 deaths | Bhutan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Bhutan or Malta?
- Bhutan, at 39.56 deaths against 37.73 deaths in Malta as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Bhutan and Malta?
- 1.83 deaths, with Bhutan ahead.
- How many years of comparable data are there for Bhutan and Malta?
- 35 years are reported by both, from 1990 to 2024.
- How do Bhutan and Malta rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Bhutan ranks 138th and Malta ranks 140th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.